Specifications TableSubjectOphthalmologySpecific subject areaRisk factor and treatment target in glaucomaType of dataTable, FigureHow data were acquiredRetrospective analysis of a case-control dataData formatRaw and analyzed dataParameters for data collectionAccording to the inclusion/ exclusion criteriaDescription of data collectionThe case-control data were conducted from April to December 2017 and 100 PACG, 100 POAG and 200 controls were consecutively recruited. Participants' ocular parameters were collected from the standardized ophthalmic examination; serum nitrotyrosine levels were measured by competitive ELISA kit and other serum biochemical indices were acquired by respective commercially available kits in Roche biochemical automatic analyzer.Data source locationEye & ENT Hospital, Fudan University, Shanghai, ChinaData accessibilityWith the articleRelated research articleYuan Lei, Yanting Gao, Maomao Song, Wenjun Cao, Xinghuai Sun, Peroxynitrite is a novel risk factor and treatment target of glaucoma, Nitric Oxide 99 (2020) 17-24. Doi: 10.1016/j.niox.2020.03.006.

Value of the Data {#sec0001a}
=================

•The data are very important to the glaucoma and nitric oxide research community since a large set of clinical data from PACG and POAG patients are reported.•The clinical data may be used by basic science researchers for further insights into the mechanism of action of peroxynitrite in glaucoma etiology.•The clinical data can also be used to design further experimental models to understand how peroxynitrite contributes to ocular hypertension.

1. Data Description {#sec0001}
===================

From April to December 2017, the case-control data were collected in the Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Fudan University. One hundred primary angle closure glaucoma (PACG), one hundred primary open angle glaucoma (POAG) patients and two hundred control participants were consecutively recruited.

[Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"} listed baseline characteristics data and serum NT level in PACG or POAG patients stratified by gender. There was no difference in serum NT levels of PACG or POAG patients of different gender.Table 1Baseline characteristics and nitrotyrosine level of primary angle-closure glaucoma patients stratified by genderTable 1Demographic ParametersMale (n=40)Female (n=60)*p* valueage, y61.78±10.1962.80±10.600.497duration of disease, y1.03±2.500.87±2.950.664intraocular pressure, mmHg23.57±11.1520.44±12.32**[0.040]{.ul}**mean deviation, dB13.99±8.8112.02±8.010.271vertical cup-to-disc ratio0.68±0.230.62±0.230.162axial length, mm22.57±0.9522.19±0.82[0.005]{.ul}central corneal thickness, µm553.08±34.85547.68±48.960.255anterior chamber depth, mm2.00±0.552.05±0.930.629total triglyceride, mmol/L1.53±0.981.58±1.000.825total cholesterol, mmol/L4.48±0.765.05±0.96**[0.002]{.ul}**gamma-glutamyl transferase, U/L27.60±19.3419.17±10.30**[0.010]{.ul}**uric acid, mmol/L0.37±0.090.26±0.07**≤[0.001]{.ul}**total bilirubin, µmol/L14.80±8.1810.77±4.960.060nitrotyrosine, nmol/L1,868.17±427.131,768.77±410.170.192[^2]Table 2Baseline characteristics and nitrotyrosine level of primary open angle glaucoma patients stratified by genderTable 2Demographic ParametersMale (n=59)Female (n=41)*p* valueage, y51.42±16.9152.20±14.940.798duration of disease, y2.85±3.392.59±4.430.289intraocular pressure, mmHg22.27±8.7020.37±7.260.209mean deviation, dB17.96±8.8312.60±9.07**[0.004]{.ul}**vertical cup-to-disc ratio0.85±0.120.77±0.15**[0.008]{.ul}**axial length, mm25.32±2.4024.98±2.030.464central corneal thickness, µm542.17±40.27530.48±30.670.255anterior chamber depth, mm2.98±0.642.85±0.500.206total triglyceride, mmol/L2.04±1.601.68±1.030.437total cholesterol, mmol/L4.54±0.804.99±1.03**[0.022]{.ul}**gamma-glutamyl transferase, U/L20.93±20.4920.17±14.59**≤[0.001]{.ul}**uric acid, mmol/L0.37±0.090.28±0.74**≤[0.001]{.ul}**total bilirubin, µmol/L14.04±7.1410.83±5.81**[0.006]{.ul}**nitrotyrosine, nmol/L1,734.04±460.741,696.46±405.730.716[^3]

[Tables 3](#tbl0003){ref-type="table"} and [4](#tbl0004){ref-type="table"} showed ocular parameters and serum NT level in PACG or POAG subjects stratified according to glaucoma severity. Based on MD, there was no significant difference regarding serum NT level with the severity of PACG or POAG (mild, n=30; moderate, n=24; sever, n=19; blinding, n=27, p\>0.05, in [Table 3](#tbl0003){ref-type="table"} for PACG; mild, n=9; moderate, n=20; sever, n=21; blinding, n=40; p\>0.05, in [Table 4](#tbl0004){ref-type="table"} for POAG).Table 3Ocular parameters and serum nitrotyrosine level of primary angle-closure glaucoma subjects, stratified according to glaucoma severityTable 3Demographic ParametersMild(n=30)Moderate(n=24)Severe(n=19)Blinding(n=27)*p* valueage, y60.07±10.1263.33±8.6564.00±10.6863.00±11.960.402duration of disease, y0.80±2.091.42±4.140.84±2.580.70±2.030.760intraocular pressure, mmHg33.27±12.4235.65±13.2828.29±14.1138.10±13.620.114mean deviation, dB3.64±1.689.03±2.0316.07±2.7724.05±2.11**≤[0.001]{.ul}**[a](#tb3fn1){ref-type="table-fn"}vertical cup-to-disc ratio0.53±0.170.56±0.190.65±0.230.84±0.17**≤[0.001]{.ul}**[b](#tb3fn2){ref-type="table-fn"}axial length, mm22.22±0.7322.24±1.2822.38±0.8022.51±0.670.587central corneal thickness, µm547.93±32.25560.52±55.69548.53±59.09543.48±29.720.832anterior chamber depth, mm2.08±0.811.82±0.612.08±1.052.13±0.750.558nitrotyrosine, nmol/L1,757.14±381.291,834.94±410.711,898.16±526.701,779.08±388.140.675[^4][^5][^6]Table 4Ocular parameters and serum nitrotyrosine level in primary open angle glaucoma subjects, stratified according to glaucoma severityTable 4Demographic ParametersMild(n=19)Moderate(n=20)Severe(n=21)Blinding(n=40)*p* valueage, y48.21±15.4852.90±13.4556.14±17.4750.53±16.740.336duration of disease, y1.74±3.433.40±5.133.05±3.152.73±3.620.297intraocular pressure, mmHg27.14±12.8830.96±11.0929.93±15.0726.22±6.930.484mean deviation, dB2.87±1.599.00±1.8415.54±2.3425.39±3.62**≤[0.001]{.ul}**[a](#tb4fn1){ref-type="table-fn"}vertical cup-to-disc ratio0.73±0.170.75±0.150.85±0.080.89±0.09**≤[0.001]{.ul}**[b](#tb4fn2){ref-type="table-fn"}axial length, mm24.80±1.6425.43±2.5625.23±1.9625.20±2.510.862central corneal thickness, µm551.11±30.89525.85±36.49527.14±26.88542.50±41.970.076anterior chamber depth, mm2.84±0.573.11±0.673.01±0.492.83±0.590.157nitrotyrosine, nmol/L1,654.99±392.081,777.71±482.611,779.46±359.501,687.40±477.470.535[^7][^8][^9]

[Table 5](#tbl0005){ref-type="table"} listed the methods and intra- and inter-assay coefficient of variations (CV).Table 5Methods, intra- and inter-assay CV.Table 5Biochemical indicesMethodIntra-assay CV (%)Inter-assay CV (%)total triglyceride, mmol/Lcolorimetry≤0.9≤1.9total cholestero, mmol/Lenzymatic colorimetry≤0.6≤1.6gamma-glutamyl transferase, U/Lenzymatic colorimetry≤3.3≤3.7uric acid, mmol/Lcolorimetry≤0.6≤1.3total bilirubi, µmol/Ldiazotization≤2.5≤3.3[^10]

[Figs. 1](#fig0001){ref-type="fig"} and [2](#fig0002){ref-type="fig"} showed the association between age, gender, biochemical indices and PACG or POAG. Multivariable logistic regression analysis indicated that the risk of developing PACG were significantly associated with serum TG and UA levels (OR=1.638, 95%CI: 1.059-2.531, p=0.026 for TG, OR=0.003, 95%CI: 0-0.461, p=0.024 for UA). There was no association between age, gender, serum total cholesterol (TC), GGT, TB, total protein (TP) levels and PACG ([Fig. 1](#fig0001){ref-type="fig"}). Serum TG, GGT, TB levels were significantly associated with POAG (OR=2.00, 95%CI: 1.363-2.934, p\<0.001 for TG; OR=0.972, 95%CI: 0.949-0.996, p=0.022 for GGT; OR=1.115, 95%CI: 1.042-1.194, p=0.002 for TB). There was no association between age, gender, serum TC, UA, TP levels and POAG ([Fig. 2](#fig0002){ref-type="fig"}).Fig. 1Forest plot of the association between age, gender, biochemical indices and PACG. The overall OR displayed with black diamonds. 95% CI displayed with horizontal lines. No effect displayed in dashed vertical line (OR=1.0). PACG: primary angle closure glaucoma, CI: confidence interval, TG: total triglyceride, TC: total cholesterol, GGT: gamma-glutamyl transferase, UA: uric acid, TB: total bilirubin, TP: total protein.Fig. 1Fig. 2Forest plot of the association between age, gender, biochemical indices and POAG. The overall OR displayed with black diamonds. 95% CI displayed with horizontal lines. No effect displayed in dashed vertical line (OR=1.0). POAG: primary open angle glaucoma, CI: confidence interval, TG: total triglyceride, TC: total cholesterol, GGT: gamma-glutamyl transferase, UA: uric acid, TB: total bilirubin, TP: total protein.Fig. 2

2. Experimental Design, Materials, and Methods {#sec0002}
==============================================

2.1. Participants {#sec0003}
-----------------

PACG patients (n=100) and POAG patients (n=100) were consecutively recruited from the Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Fudan University between April 2017 and December 2017. Subjects participated in annual health screenings during this period were consecutively recruited as normal controls (n=200).

Each PACG or POAG patient accepted a standardized ophthalmic examination performed by glaucoma specialists. Those included assessments of slit-lamp biomicroscopy, refractive status, fundus examination, gonioscopy, intraocular pressure (IOP), axial length (AL), central corneal thickness (CCT), anterior chamber depth (ACD) and visual field (VF) examination. An automated perimeter (Octopus; Haag-Streit AG, Koeniz, Switzerland) was used to measure mean deviation (MD). A Goldmann applanation tonometry was used to measure IOP. A retinal camera (TRC- NW200, Topcon Corp., Tokyo, Japan) was used to acquire Fundus photography. AL, ACD, and CCT were acquired by A-scan ultrasound (A-Scan Pachymeter; Ultrasonic, Exton, PA, USA). Each normal control also accepted a basic ophthalmic examination by an expert ophthalmologist. Those included assessments of slit-lamp biomicroscopy, refractive status, and fundus examination. We chose data from the right eye even if both eyes of the patents diagnosed with glaucoma.

2.2. Inclusion/exclusion criteria of PACG and POAG {#sec0004}
--------------------------------------------------

PACG subjects: 1) Age≥18 years old; 2) IOP\>21 mmHg; 3) at least 180 degrees of iridotrabecular contact; 4) glaucomatous optic neuropathy with vertical cup-to-disc ratio (VCDR) ≥0.7; 5) peripheral visual loss; 6) exclude secondary causes of glaucoma; 7) exclude other eye disorders (besides senile cataracts); 8) exclude infectious or systemic diseases such as hyperuricemia, diabetes, cardiac, acute or chronic inflammation, autoimmune disease, and cancer.

PACG can be classified according to the timing or suddenness of onset into acute PACG (APACG) or chronic PACG (CPACG) [@bib0002]. APACG, a severe type, was defined as 1) IOP\>28 mmHg; 2) at least two of those symptoms: nausea, vomiting, ocular or periocular pain, or antecedent history of intermittent blurring of vision; and 3) at least three of those signs: corneal epithelial edema, conjunctival injection, shallow anterior chamber or mid-dilated nonreactive pupil. CPACG, also a severe type, diagnosed according to the PACG criteria listed above with no acute signs or symptoms. Subjects who received glaucoma medications were included too. We chose data from the right eye even if both eyes of the patents diagnosed with glaucoma. Patients can be divided into four subgroups based on perimetry, i.e., mild (MD≤6 dB), moderate (12 dB≥MD\>6 dB), severe (20 dB≥MD\>12 dB) and blinding (MD\>20 dB) [@bib0003].

POAG subjects: 1) Age≥18 years old; 2) IOP\>21 mmHg; 3) glaucomatous optic neuropathy with at least two of the following characteristics: VCDR ≥0.7 in either eye, VCDR asymmetry≥0.2, diffuse or focal neural rim thinning, an optic disc hemorrhage, a notch and nerve fiber layer defect; 4) corresponding VF defect; 5) a normal anterior chamber and open angle; 6) exclude other eye disorders (besides senile cataracts); 7) exclude infectious or systemic diseases such as hyperuricemia, diabetes, cardiac, acute or chronic inflammation, autoimmune disease, and cancer.

Subjects who received glaucoma medications were included too. We chose data from the right eye even if both eyes of the patents diagnosed with glaucoma. Four subgroups of POAG patients generated with the same methods used in PACG.

2.3. Inclusion/ exclusion criteria of the control group {#sec0005}
-------------------------------------------------------

1\) Age≥18 years old. 2) The controls had normal physical and ocular examination data, no positive family history of glaucoma, and no infection or systemic diseases such as acute or chronic inflammation, cardiovascular diseases, hyperuricemia, diabetes mellitus, autoimmune disease, and cancer. 3) All normal controls were randomly divided into two groups (n=100 per group), which were age-matched and gender-matched to PACG group and POAG group, respectively.

2.4. Biochemical measurement {#sec0006}
----------------------------

Blood samples were obtained from subjects having fasted for 8 hours in the morning, which collected from the anterior elbow veins of the participants via anticoagulant tube. For complete clot formation, tubes were put in an vertical position for 30 min at room temperature, and then tubes were centrifuged at 2593g for 10 minutes. Then serum samples were collected and stored at -80°C within an hour. Serum levels of TG, TC, GGT, UA, TB and TP were obtained using respective commercially available kits (Roche Diagnostics GmbH, Mannheim, Germany). [Table 5](#tbl0005){ref-type="table"} listed the detection method and inter- and intra-assay CVs of those biochemical indices guided by the manufacturer. Further, we analyzed internal controls daily over the 3 years. The results showed that there was no significant changes of the values with typical monthly CVs of 2% to 4%.

2.5. Measurement of NT {#sec0007}
----------------------

Using competitive ELISA kits (Hycult Biotechnology b.v., Uden, The Netherlands), serum NT levels were measured following the manufacturer\'s instructions. The intensities of the color of the samples were detected at 450nm using an automatic microplate reader. The intra- and inter-assay CVs here were \<10% respectively.

3. Statistical analysis {#sec0008}
=======================

Data were analyzed using SPSS for Windows version 24.0 software (SPSS, Chicago, IL, USA). Independent Student\'s t-test and Mann-Whitney U test were used to compare the baseline characteristics and NT level in PACG or POAG patients stratified by gender ([Table 1](#tbl0001){ref-type="table"},[2](#tbl0002){ref-type="table"}). The χ2 test, one-way ANOVA and Kruskal-Wallis test followed by Bonferroni multiple comparison test were used to compare ocular parameters and serum NT levels in PACG or POAG subjects stratified by glaucoma severity ([Table 3](#tbl0003){ref-type="table"},[4](#tbl0004){ref-type="table"}). The association between age, gender, biochemical indices and PACG or POAG was analyzed by multivariable logistic regression analysis ([Fig. 1](#fig0001){ref-type="fig"},[2](#fig0002){ref-type="fig"}). In all cases, a P-value \<0.05 was considered to be statistically significant.

Appendix. Supplementary material {#sec0010}
================================
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